TEVA
Stock Details
TEVA is Teva Pharmaceutical Industries Limited's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 8.35$. Average daily volumn in 3 months 9.97M. Market cap 8.76B
Stock symbol : TEVA. Exchange : NYSE. Currency : USD Lastest price : 7.89$. Total volume : 10.99M. Market state CLOSED Click reload if you want to check the lastest price on market!!!
Teva Pharmaceutical Industries Limited (TEVA)
Last Price
7.89$Change
0.37Volume
10.99M
| Previous Close | 7.52 |
| Open | 7.51 |
| Day Range | 7.42-7.91 |
| Bid | 7.74 x 21.5k |
| Ask | 7.89 x 27k |
| Volume | 10.99M |
| Average Volume | 9.97M |
| Market Cap | 8.76B |
| Beta | 1.18 |
| 52 Week Range | 7.23-10.50 |
| Trailing P/E | N/A |
| Foward P/E | 3.05 |
| Dividend (Yield %) | N/A |
| Ex-Dividend Date | 2017-11-27 |
Financial Details
Organization
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells ac... tive pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Market Cap:
8.76BRevenue:
15.88BTotal Assets:
47.67BTotal Cash:
2.17B
News about "Teva Pharmaceutical Industries Limited"
IFM Investors Pty Ltd Buys 30,190 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Source from : Defense World - 2 days ago
IFM Investors Pty Ltd boosted its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Rating) by 22.3% in the first quarter, HoldingsChannel reports. The firm owned 165,346 shares of the ...See details»
Sumitomo Mitsui DS Asset Management Company Ltd Has $512,000 Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Source from : Defense World - 1 days ago
Sumitomo Mitsui DS Asset Management Company Ltd trimmed its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Rating) by 18.8% in the first quarter, Holdings Channel.com reports. The ...See details»
IFM Investors Pty Ltd Boosts Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Source from : ETF Daily News - 2 days ago
Shares of NYSE:TEVA opened at $7.89 on Friday. The stock’s 50-day moving average price is $8.31 and its 200-day moving average price is $8.51. Teva Pharmaceutical Industries Limited has a 12 ...See details»
Teva Pharmaceutical Appoints Eric Hughes As Chief Medical Officer
Source from : Nasdaq - 3 days ago
Hughes joins Teva with nearly 20 years of experience in all phases of drug development in leading global pharmaceutical companies, most recently as Senior Vice President of Clinical Development and ...See details»
Teva Pharmaceutical Industries (NYSE:TEVA) investors are sitting on a loss of 76% if they invested five years ago
Source from : YAHOO!Finance - 7 days ago
We're definitely into long term investing, but some companies are simply bad investments over any time frame. It ...See details»
Teva Pharmaceutical Industries Limited (TEVA) Quarterly Performance is -5.26%: Here is the Surprise Factor
Source from : investchronicle - 7 days ago
At the end of the latest market close, Teva Pharmaceutical Industries Limited (TEVA) was valued at $7.74. In that particular session, Stock kicked-off at the price of $7.77 while reaching the peak ...See details»
August 12th Options Now Available For Teva Pharmaceutical Industries
Source from : Nasdaq - 4 days ago
Investors in Teva Pharmaceutical Industries Ltd (Symbol: TEVA) saw new options begin trading today, for the August 12th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...See details»
DNB Asset Management AS Has $1.24 Million Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Source from : ETF Daily News - 8 days ago
Teva Pharmaceutical Industries Limited has a 52-week low of $7.23 and a 52-week high of $10.50. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.73 and a current ratio of 1.07.See details»
Teva Announces Appointment of New Global R&D and Chief Medical Officer
Source from : Stockhouse - 3 days ago
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today the appointment of Eric A. Hughes, MD, PhD as Executive Vice President, Global R&D and Chief Medical Officer. Dr. Hughes will ...See details»
New Suit - Class Action
Source from : Law - 7 days ago
Counsel have not yet appeared for the defendants. The case is 2:21-cv-00477, King County et al v. Teva Pharmaceutical Industries Ltd et al.See details»
Generic Drugs Market to Observe Exponential Growth By 2022 to 2030 | Teva Pharmaceuticals Industries Ltd, Mylan N.V, Novartis AG
Source from : Digital Journal - 11 days ago
New Jersey, United States-Generic Drugs Market 2022 – 2030, Size, Share, and Trends Analysis Research Report Segmented with Type, Component, Application, Region, and Forecast The Generic Drugs ...See details»
Teva Announces Settlement with Aurobindo Resolving AUSTEDO® (deutetrabenazine) Patent Dispute
Source from : The Globe and Mail - 6 days ago
Teva Branded Pharmaceutical Products R&D, Inc. and Auspex Pharmaceuticals, Inc., U.S. affiliates of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), have reached an agreement with Aurobindo ...See details»
New Suit - Product Liability
Source from : Law - 10 days ago
CVS Health, Teva Pharmaceutical Industries, Walmart and other defendants ... The case is 1:20-cv-08485, Brewster v. Aurobindo Pharma LTD. et al.See details»
Interstitial Cystitis Drugs Market Recorded 4.81% Y-O-Y Growth Rate in 2021| Evolving Opportunities with Perrigo Co. Plc & Pfizer Inc | Technavio
Source from : WFMZ-TV - 5 days ago
The Interstitial Cystitis Drugs Market report provides a detailed analysis of the competitive scenario, the pre-and post-COVID-19 impact on businesses, and the market ...See details»